eligibility_summary
Eligible: treatment‑naïve adults with CLL requiring treatment, ECOG 0–2, measurable disease on CT/MRI, adequate liver (AST/ALT ≤2.5×ULN, bilirubin <3×ULN) and renal function (creatinine clearance ≥50 mL/min). Exclude: prior systemic CLL therapy, prolymphocytic leukemia, suspected/history of Richter’s transformation, CNS involvement, history of PML, uncontrolled hypertension. Other criteria may apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, open-label randomized trial in previously untreated CLL comparing: 1) Sonrotoclax (BGB‑11417) + Zanubrutinib vs 2) Venetoclax + Obinutuzumab. Mechanisms/types: Sonrotoclax—oral small‑molecule, highly selective BCL‑2 inhibitor (BH3‑mimetic) that restores mitochondrial apoptosis in CLL cells, Zanubrutinib—oral covalent Bruton’s tyrosine kinase (BTK) inhibitor that blocks B‑cell receptor (BCR) signaling, reducing proliferation/survival, Venetoclax—oral BCL‑2 inhibitor (BH3‑mimetic) inducing apoptosis, Obinutuzumab—IV type II anti‑CD20 monoclonal antibody that depletes B cells via ADCC, direct cell death, and complement (CDC). Targets: malignant CD20+ B cells, BCL‑2 anti‑apoptotic pathway, BTK/BCR signaling, immune effector ADCC/CDC pathways.